Innocan Pharma Obtains Receipt For Final Base Shelf Prospectus

GW
Gowling WLG

Contributor

Gowling WLG is an international law firm built on the belief that the best way to serve clients is to be in tune with their world, aligned with their opportunity and ambitious for their success. Our 1,400+ legal professionals and support teams apply in-depth sector expertise to understand and support our clients’ businesses.
On May 17, 2022, Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) ("Innocan") announced that it had filed and obtained a receipt for a final short form base shelf prospectus...
Canada Food, Drugs, Healthcare, Life Sciences

On May 17, 2022, Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) ("Innocan") announced that it had filed and obtained a receipt for a final short form base shelf prospectus with the securities regulatory authorities in each of the provinces and territories of Canada.

The base shelf prospectus allows Innocan to qualify the distribution of up to $100,000,000 of common shares, warrants, units, and subscription receipts or any combination thereof, during the 25-month period that the base shelf prospectus remains effective. 

Innocan is an Israeli pharmaceutical technology company that focuses on the development of several drug delivery platforms containing CBD. 

Gowling WLG advised Innocan with respect to the filing of the prospectus with a team that included Jason Saltzman, Josh Rosen and Joseph McDonald.

Read the original article on GowlingWLG.com

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More